Advanced Cancer Patient Knowledge of and Attitudes towards Tumor Molecular Profiling

Grace Davies, Phyllis Butow, Christine E Napier, Nicci Bartley, Ilona Juraskova, Bettina Meiser, Mandy L Ballinger, David M Thomas, Timothy E Schlub, Megan C Best, members of the PiGeOn Project, Grace Davies, Phyllis Butow, Christine E Napier, Nicci Bartley, Ilona Juraskova, Bettina Meiser, Mandy L Ballinger, David M Thomas, Timothy E Schlub, Megan C Best, members of the PiGeOn Project

Abstract

Limited research has indicated that despite their overwhelming interest in tumor molecular profiling (MP),1 cancer patients have poor knowledge about MP. The current study aimed to investigate demographic and psychological predictors of knowledge and perceived importance of MP in an advanced cancer patient cohort. Eligible participants had advanced solid cancers of any histological type with sufficient accessible tissue for MP and were enrolled in the Molecular Screening and Therapeutics (MoST) Program. A questionnaire was completed by 1074 participants (91% response rate) after consent, prior to undergoing MP. Overall, participants had poor to moderate knowledge of MP, yet perceived MP to have high importance. Higher education, speaking English at home, and greater satisfaction with the decision to undergo MP were associated with higher knowledge scores. More negative attitudes towards uncertainty, greater self-efficacy to cope with results, and lower perceived likelihood of cancer progression were associated with greater perceived importance of MP. Less educated participants and those who do not speak English at home will need clear explanations, visual aids and ample opportunity to ask questions about MP at the time of their decision-making. Clinicians also need to consider psychological factors relevant to patients' decision to pursue MP. Given the increased awareness of and demand for cancer genomic information and the rapidly changing nature of the actionability of MP, these findings will help inform an important ongoing debate on how to facilitate ethical and informed consent and manage patient expectations about personalized treatments.

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

References

    1. Glaire M.A., Brown M., Church D.N., Tomlinson I. Cancer predisposition syndromes: lessons for truly precision medicine. J. Pathol. 2017;241:226–235.
    1. Yushak M.L., Han G., Bouberhan S., Epstein L., DiGiovanna M.P., Mougalian S.S., Sanft T.B., Abu-Khalaf M.M., Chung G.G., Stein S.M. Patient preferences regarding incidental genomic findings discovered during tumor profiling. Cancer. 2016;122:1588–1597.
    1. Miller F.A., Hayeems R.Z., Bytautas J.P., Bedard P.L., Ernst S., Hirte H., Hotte S., Oza A., Razak A., Welch S. Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. Eur. J. Hum. Genet. 2013;22:391–395.
    1. Halpern J., Paolo D., Huang A. Informed consent for early-phase clinical trials: therapeutic misestimation, unrealistic optimism and appreciation. J. Med. Ethics. 2019;45:384–387.
    1. McGuire A.L., Beskow L.M. Informed consent in genomics and genetic research. Annu. Rev. Genomics Hum. Genet. 2010;11:361–381.
    1. Horton R., Lucassen A. Consent and autonomy in the genomics era. Curr. Genet. Med. Rep. 2019;7:85–91.
    1. Yanes T., Willis A.M., Meiser B., Tucker K.M., Best M. Psychosocial and behavioral outcomes of genomic testing in cancer: a systematic review. Eur. J. Hum. Genet. 2019;27:28–35.
    1. Blanchette P.S., Spreafico A., Miller F.A., Chan K., Bytautas J., Kang S., Bedard P.L., Eisen A., Potanina L., Holland J. Genomic testing in cancer: patient knowledge, attitudes, and expectations. Cancer. 2014;120:3066–3073.
    1. Yusuf R.A., Rogith D., Hovick S.R.A., Peterson S.K., Burton‐Chase A.M., Fellman B.M., Li Y., McKinney C., Bernstam E.V., Meric‐Bernstam F. Attitudes toward molecular testing for personalized cancer therapy. Cancer. 2015;121:243–250.
    1. Gray S.W., Hicks-Courant K., Lathan C.S., Garraway L., Park E.R., Weeks J.C. Attitudes of patients with cancer about personalized medicine and somatic genetic testing. J. Oncol. Pract. 2012;8:329–335.
    1. Pellegrini I., Rapti M., Extra J.M., Petri‐Cal A., Apostolidis T., Ferrero J.M., Bachelot T., Viens P., Julian‐Reynier C., Bertucci F. Tailored chemotherapy based on tumour gene expression analysis: breast cancer patients' misinterpretations and positive attitudes. Eur. J. Cancer Care. 2012;21:242–250.
    1. Liang R., Meiser B., Smith S., Kasparian N.A., Lewis C.R., Chin M., Long G.V., Ward R., Menzies A.M., Harris‐Wai J.N. Advanced cancer patients’ attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study. Eur. J. Cancer Care. 2017;26
    1. Best M.C., Bartley N., Jacobs C., Juraskova I., Goldstein D., Newson A.J., Savard J., Meiser B., Ballinger M., Napier C. Patient perspectives on molecular tumor profiling: "Why wouldn't you?". BMC Cancer. 2019;19:753.
    1. Manne S.L., Chung D.C., Weinberg D.S., Vig H.S., Catts Z., Cabral M.K., Shannon K., Meropol N.J. Knowledge and attitudes about microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. Cancer Epidemiol. Biomark. Prev. 2007;16:2110–2117.
    1. DeFrank J.T., Salz T., Reeder-Hayes K., Brewer N.T. Who gets genomic testing for breast cancer recurrence risk? Public Health Genomics. 2013;16:215–222.
    1. Maddux J.E., Rogers R.W. Protection motivation and self-efficacy: a revised theory of fear appeals and attitude change. J. Exp. Soc. Psychol. 1983;19:469–479.
    1. Rogers, R.W., and Prentice-Dunn, S. (1997). Protection motivation theory. In Handbook of health behavior research 1: Personal and social determinants. (New York, NY, US, Plenum Press), pp 113-132.
    1. Thavaneswaran S., Sebastian L., Ballinger M., Best M., Hess D., Lee C.K., Sjoquist K.M., Hague W.E., Butow P.N., Simes R.J. Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal‐seeking studies of targeted therapies for rare and neglected cancers. Med. J. Aust. 2018;209:354–355.
    1. Best M., Newson A.J., Meiser B., Juraskova I., Goldstein D., Tucker K., Ballinger M.L., Hess D., Schlub T.E., Biesecker B. The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling. BMC Cancer. 2018;18:389.
    1. Mann G.J., Thorne H., Balleine R.L., Butow P.N., Clarke C.L., Edkins E., Evans G.M., Fereday S., Haan E., Gattas M. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res. 2006;8:R12.
    1. Mitchell G., Ballinger M.L., Wong S., Hewitt C., James P., Young M.-A., Cipponi A., Pang T., Goode D.L., Dobrovic A. High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort. PLoS One. 2013;8
    1. Holmes-Rovner M., Kroll J., Schmitt N., Rovner D.R., Breer M.L., Rothert M.L., Padonu G., Talarczyk G. Patient satisfaction with health care decisions: the Satisfaction with Decision Scale. Med. Decis. Mak. 1996;16:58–64.
    1. Rosenberg S.M., Tracy M.S., Meyer M.E., Sepucha K., Gelber S., Hirshfield-Bartek J., Troyan S., Morrow M., Schapira L., Come S. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer. Ann. Intern. Med. 2013;159:373–381.
    1. Braithwaite D., Sutton S., Steggles N. Intention to participate in predictive genetic testing for hereditary cancer: The role of attitude toward uncertainty. Psychol. Health. 2002;17:761–772.
    1. Kasparian N.A., Meiser B., Butow P.N., Simpson J.M., Mann G.J. Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet. Med. 2009;11:265–278.
    1. Hay J., Kaphingst K., Baser R., Li Y., Hensley-Alford S., McBride C. Skin cancer concerns and genetic risk information-seeking in primary care. Public Health Genomics. 2012;15:57–72.
    1. Barbor M. Precision medicine: hope or hype? 2018.
    1. Centre for Genetics Education Life insurance products and genetic testing in Australia. 2019.
    1. Budych K., Helms T.M., Schultz C. How do patients with rare diseases experience the medical encounter? Exploring role behavior and its impact on patient–physician interaction. Health Policy. 2012;105:154–164.
    1. Lea S., Martins A., Morgan S., Cargill J., Taylor R.M., Fern L.A. Online information and support needs of young people with cancer: a participatory action research study. Adolesc. Health Med. Ther. 2018;9:121–135.
    1. McNutt L., Waltermaurer E., Bednarczyk R., Carlson B., Kotval J., McCauley J., Campbell J., Ford D. Are we misjudging how well informed consent forms are read? J. Empir. Res. Hum. Res. Ethics. 2008;3:89–97.
    1. Almario C.V. The effect of digital health technology on patient care and research. Gastroenterol. Hepatol. 2017;13:437–439.
    1. Dieng M., Watts C.G., Kasparian N.A., Morton R.L., Mann G.J., Cust A.E. Improving subjective perception of personal cancer risk: systematic review and meta-analysis of educational interventions for people with cancer or at high risk of cancer. Psychooncology. 2014;23:613–625.
    1. Lerman C., Lustbader E., Rimer B., Daly M., Miller S., Sands C., Balshem A. Effects of individualized breast cancer risk counseling: a randomized trial. J. Natl. Cancer Inst. 1995;87:286–292.
    1. Hollands G.J., French D.P., Griffin S.J., Prevost A.T., Sutton S., King S., Marteau T.M. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. Br. Med. J. 2016;352:i1102.
    1. Nilsson M.E., Maciejewski P.K., Zhang B., Wright A.A., Trice E.D., Muriel A.C., Friedlander R.J., Fasciano K.M., Block S.D., Prigerson H.G. Mental health, treatment preferences, advance care planning, location, and quality of death in advanced cancer patients with dependent children. Cancer. 2009;115:399–409.
    1. Muriel A.C., Moore C.W., Baer L., Park E.R., Kornblith A.B., Pirl W., Prigerson H., Ing J., Rauch P.K. Measuring psychosocial distress and parenting concerns among adults with cancer. Cancer. 2012;118:5671–5678.
    1. Croyle R.T., Dutson D.S., Tran V.T., Sun Y.C. Need for certainty and interest in genetic testing. Women Health. 1995;1:329–339.
    1. Tibben A., Frets P.G., Van De Kamp J.J.P., Niermeijer M.F., Der Vlis M.V., Roos R.A.C., Rooymans H.G.M., Van Ommen G.J.B., Verhage F. On attitudes and appreciation 6 months after predictive DNA testing for Huntington disease in the Dutch program. Am. J. Med. Genet. 1993;48:103–111.
    1. Decruyenaere M., Evers-Kiebooms G., Van den Berghe H. Perception of predictive testing for Huntington's disease by young women: preferring uncertainty to certainty? J. Med. Genet. 1993;30:557–561.
    1. Kessler L., Collier A., Brewster K., Smith C., Weathers B., Wileyto E.P., Halbert C.H. Attitudes about genetic testing and genetic testing intentions in African American women at increased risk for hereditary breast cancer. Genet. Med. 2005;7:230–238.
    1. Cameron L.D., Reeve J. Risk perceptions, worry, and attitudes about genetic testing for breast cancer susceptibility. Psychol. Health. 2006;21:211–230.
    1. Catenacci D.V.T., Amico A.L., Nielsen S.M., Geynisman D.M., Rambo B., Carey G.B., Gulden C., Fackenthal J., Marsh R.D., Kindler H.L. Tumor genome analysis includes germline genome: Are we ready for surprises? Int. J. Cancer. 2015;136:1559–1567.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera